368 related articles for article (PubMed ID: 36503344)
41. Tertiary lymphoid structures in cancer and beyond.
Dieu-Nosjean MC; Goc J; Giraldo NA; Sautès-Fridman C; Fridman WH
Trends Immunol; 2014 Nov; 35(11):571-80. PubMed ID: 25443495
[TBL] [Abstract][Full Text] [Related]
42. Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients.
Cai D; Wang X; Yu H; Bai C; Mao Y; Liang M; Xia X; Liu S; Wang M; Lu X; Du J; Shen X; Guan W
Clin Transl Immunology; 2024; 13(2):e1489. PubMed ID: 38322490
[TBL] [Abstract][Full Text] [Related]
43. Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer.
Yamaguchi K; Ito M; Ohmura H; Hanamura F; Nakano M; Tsuchihashi K; Nagai S; Ariyama H; Kusaba H; Yamamoto H; Oda Y; Nakamura M; Akashi K; Baba E
Oncoimmunology; 2020; 9(1):1724763. PubMed ID: 32117589
[TBL] [Abstract][Full Text] [Related]
44. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract][Full Text] [Related]
45. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
46. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
47. [Tertiary lymphoid structures in cancer: From biology to therapeutic guides].
Quesada S; Lebreton C; Caux C; Italiano A; Dubois B
Bull Cancer; 2023 Jun; 110(6):657-664. PubMed ID: 37150731
[TBL] [Abstract][Full Text] [Related]
48. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
Peng H; Wu X; Zhang C; Liang Y; Cheng S; Zhang H; Shen L; Chen Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):153. PubMed ID: 38519621
[TBL] [Abstract][Full Text] [Related]
49. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
50. Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival.
Mokhtari Z; Rezaei M; Sanei MH; Dehghanian A; Faghih Z; Heidari Z; Tavana S
Front Oncol; 2023; 13():1069696. PubMed ID: 37035199
[TBL] [Abstract][Full Text] [Related]
51. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.
Li H; Liu H; Fu H; Li J; Xu L; Wang G; Wu H
Front Immunol; 2021; 12():648812. PubMed ID: 34122408
[TBL] [Abstract][Full Text] [Related]
52. Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors.
Lin Q; Tao P; Wang J; Ma L; Jiang Q; Li J; Zhang G; Liu J; Zhang Y; Hou Y; Lu W; Xue R; Tong H
Oncoimmunology; 2020; 9(1):1747339. PubMed ID: 32313726
[TBL] [Abstract][Full Text] [Related]
53. Development of Tools for the Selective Visualization and Quantification of TLS-Immune Cells on Tissue Sections.
Klein C; Devi-Marulkar P; Dieu-Nosjean MC; Germain C
Methods Mol Biol; 2018; 1845():47-69. PubMed ID: 30141007
[TBL] [Abstract][Full Text] [Related]
54. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.
Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H
Hepatol Int; 2024 May; ():. PubMed ID: 38767772
[TBL] [Abstract][Full Text] [Related]
55. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive analysis of tertiary lymphoid structures-related genes for prognostic prediction, molecular subtypes and immune infiltration in gastric cancer.
Zhou Q; Lan L; Wang W; Xu X; Wang W
Aging (Albany NY); 2023 Nov; 15(22):13368-13383. PubMed ID: 38015717
[TBL] [Abstract][Full Text] [Related]
57. Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.
Jia W; Yao Q; Wang Y; Mao Z; Zhang T; Li J; Nie Y; Lei X; Shi W; Song W
Front Immunol; 2022; 13():1007426. PubMed ID: 36189217
[TBL] [Abstract][Full Text] [Related]
58. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.
Xu X; Gao Y; Duan S; Ding Q; Wang X; Dai X; Zhang Y; Chen Y; Chen D
Cancer Med; 2023 Apr; 12(8):9547-9558. PubMed ID: 36880167
[TBL] [Abstract][Full Text] [Related]
59. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
[TBL] [Abstract][Full Text] [Related]
60. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
